Edition:
United States

Seattle Genetics Inc (SGEN.O)

SGEN.O on Nasdaq

63.22USD
23 Mar 2017
Change (% chg)

$0.19 (+0.30%)
Prev Close
$63.03
Open
$62.99
Day's High
$64.06
Day's Low
$62.57
Volume
658,429
Avg. Vol
1,146,083
52-wk High
$75.36
52-wk Low
$32.40

Latest Key Developments (Source: Significant Developments)

Seattle Genetics says court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics
Friday, 10 Mar 2017 07:44am EST 

Seattle Genetics Inc : Seattle Genetics- On March 9,court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics . Seattle Genetics-Temporary restraining order to remain in place pending hearing on application for preliminary injunction to be held in about 30 days .Seattle Genetics - Restraining order regarding license agreement between co and Immunomedics, Inc. regarding Sacituzumab Govitecan.  Full Article

FDA lifts hold on Seattle Genetics' phase 1 trials of vadastuximab talirine
Monday, 6 Mar 2017 06:45am EST 

Seattle Genetics Inc : FDA lifts clinical hold on seattle genetics' phase 1 trials of vadastuximab talirine . Seattle genetics inc - seattle genetics will resume two phase 1 trials of vadastuximab talirine . Seattle genetics inc - will not resume phase 1/2 trial of vadastuximab talirine monotherapy in pre- and post-allogeneic transplant aml patients . Seattle genetics inc - continuing to enroll our ongoing phase 3 randomized cascade trial in frontline older aml patients . Seattle genetics inc - we are continuing to enroll our phase 1/2 trial in frontline high-risk myelodysplastic syndrome . Seattle genetics-planned studies include phase 2 trial of vadastuximab talirine in combination with 7+3 chemotherapy in frontline younger aml patients . Seattle genetics-additional risk mitigation measures will be implemented in all vadastuximab talirine studies .Seattle genetics - will resume two phase 1 trials in aml and plan to initiate a randomized phase 2 trial during 2017 evaluating vadastuximab talirine.  Full Article

Immunomedics says to seek expedited trial regarding venBio's actions
Friday, 3 Mar 2017 10:19am EST 

Immunomedics Inc : Continue to pursue legally justified relief against venBio Select Advisor LLC and venBio's four director candidates in court . Immunomedics intends to proceed with its annual meeting scheduled for Friday . Intends to seek expedited discovery, expedited trial with respect to "questionable actions" actions employed by venBio .Says will promptly seek appropriate relief in a proceeding in Delaware chancery court.  Full Article

Immunomedics enters licensing agreement with Seattle Genetics
Friday, 10 Feb 2017 06:50am EST 

Immunomedics Inc - : Immunomedics enters into exclusive global licensing agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with potential payments of up to approximately $2 billion, plus royalties . For limited period, through Feb 19, 2017, co has right to continue negotiating with select number of parties, and accept superior proposal . Co has right to accept superior proposal, terminate proposed development, license agreement upon payment of termination fee to Seattle Genetics . Immunomedics and Seattle Genetics will each appoint representatives to serve on a joint steering committee . Immunomedics will retain right to elect to co-promote IMMU-132 in United States by participating in 50 pct of sales effort . JSC will be responsible for determining overall development, commercialization, & intellectual property strategy for IMMU-132 . Expects deal to "fulfill" its liquidity needs such that company can fund itself without additional equity raises for foreseeable future . Upon closing of transaction, Immunomedics board and management will evaluate and prioritize company's remaining clinical programs .Seattle genetics to make up to $57 million equity investment for up to 9.9 pct stake in co via immediate purchase of common stock, 3-year warrant.  Full Article

Seattle Genetics Q4 loss per share $0.39
Thursday, 9 Feb 2017 04:02pm EST 

Seattle Genetics Inc : Seattle Genetics reports fourth quarter and year 2016 financial results . Q4 loss per share $0.39 . Sees FY 2017 revenue $405 million to $445 million . Q4 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Q4 revenue $105.3 million versus I/B/E/S view $105 million .FY2017 revenue view $494.0 million -- Thomson Reuters I/B/E/S.  Full Article

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 06:59am EDT 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Seattle Genetics reports Q2 financial results
Tuesday, 26 Jul 2016 04:02pm EDT 

Seattle Genetics Inc : Sees intiating phase 2 trial of denintuzumab mafodotin (SGN-CD19a; 19A) in frontline diffuse large B-cell lymphoma during 2016. . Seattle Genetics reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S .Q2 revenue $95.4 million versus I/B/E/S view $94.1 million.  Full Article

Seattle Genetics, Inc initiates phase 1/2 trial of vadastuximab talirine
Monday, 22 Feb 2016 08:00am EST 

Seattle Genetics, Inc:Initiates phase 1/2 trial of vadastuximab talirine combination therapy for patients with untreated myelodysplastic syndrome.  Full Article

Seattle Genetics, Inc announces proposed public offering of common stock
Wednesday, 9 Sep 2015 04:01pm EDT 

Seattle Genetics, Inc:Announces proposed public offering of common stock.Says has commenced an underwritten public offering of $400 million of shares of its common stock.Says net proceeds from the offering to fund the ongoing commercialization of adcetris in the United States and Canada.  Full Article

Seattle Genetics initiates clinical trial of adcetris
Thursday, 9 Jul 2015 09:00am EDT 

Seattle Genetics:Says the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus).Lupus is a chronic autoimmune disease in which the body's own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death.ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on activated lymphocytes that are thought to play a key role in the development of autoimmune diseases, including lupus.Trial is designed to assess the safety and activity of ADCETRIS in adult patients with lupus. ADCETRIS is currently not approved for the treatment of lupus.  Full Article

More From Around the Web

Photo

Seattle Genetics to resume trials as FDA lifts clinical hold

Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.